Draghia-Akli Ruxandra
SEC CIK 2041719 · EDGAR
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| NVAX | NOVAVAX INC | Section 16 | 34.9K | — | — | 4 | 2025-11-11 | 2026-03-03 |
Most active insiders at NVAX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Draghia-Akli Ruxandra | Section 16 | — | — |
| 2 | O'Hara Elaine | EVP, Chief Strategy Off | — | — |
| 3 | Shiver John W. | Dir | — | — |
| 4 | Newton Charles W. | Dir | — | — |
| 5 | Jacobs John C | Pres, CEO, Dir | — | — |
| 6 | King Rachel K. | Dir | — | — |
| 7 | Kelly James Patrick | EVP, CFO, Treas | — | — |
| 8 | Casey Mark J | EVP, CLO | — | — |
| 9 | Alton Gregg H | Dir | — | — |
| 10 | Rodgers Richard J | Dir | — | — |
Transactions 4
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-05 | 2026-03-03 | NVAX | NOVAVAX INC | Draghia-Akli Ruxandra | EVP, Research, Development | M - OptEx | $0.00 | +26.7K | 34.9K | +325% | $0 |
| D | 2026-03-05 | 2026-03-03 | NVAX | NOVAVAX INC | Draghia-Akli Ruxandra | EVP, Research, Development | F - Tax | $9.49 | -11.3K | 23.6K | -32% | -$107.4K |
| D | 2025-11-13 | 2025-11-11 | NVAX | NOVAVAX INC | Draghia-Akli Ruxandra | Section 16 | F - Tax | $7.40 | -6,048 | 8,209 | -42% | -$44.8K |
| D | 2025-11-13 | 2025-11-11 | NVAX | NOVAVAX INC | Draghia-Akli Ruxandra | Section 16 | M - OptEx | $0.00 | +14.3K | 14.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations